| Q43543016 | 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity? |
| Q43621340 | 4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses |
| Q37739587 | 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks? |
| Q34649017 | 5-HT1F Receptor Agonists in Acute Migraine Treatment: A Hypothesis |
| Q32041979 | A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation |
| Q37686124 | Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches |
| Q31808140 | Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells |
| Q54219940 | Advances in Meningeal Immunity. |
| Q37129812 | Almotriptan in the treatment of migraine. |
| Q48260847 | Alterations in neurokinin A-, substance P- and calcitonin gene-related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the trigeminal ganglion |
| Q38742593 | An update on migraine: current understanding and future directions. |
| Q37376076 | Anatomy and development of the meninges: implications for subdural collections and CSF circulation |
| Q38162801 | Animal migraine models for drug development: status and future perspectives |
| Q34531880 | Anti-CGRP monoclonal antibodies in migraine: current perspectives |
| Q37971447 | Antidromic vasodilatation and the migraine mechanism |
| Q44873461 | Axon diameters and intradural trajectories of the dural innervation in the rat. |
| Q42116933 | Biphasic neurogenic vasodilatation in the bovine intraocular long posterior ciliary artery: involvement of nitric oxide and an additional unidentified neurotransmitter |
| Q34662470 | Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva |
| Q37384128 | CGRP and migraine: could PACAP play a role too? |
| Q42713037 | CP-93,129, a potent and selective 5-HT1B receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater |
| Q28326822 | CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges |
| Q92281834 | CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura |
| Q36360319 | Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches |
| Q33328554 | Calcitonin gene-related peptide immunoreactive nerve fibres in the dura mater encephali of the rat: experiments related to the neurogenic inflammation of meningeal structures |
| Q30466408 | Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. |
| Q36240187 | Can we develop neurally acting drugs for the treatment of migraine? |
| Q34125262 | Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy |
| Q42314880 | Changes in retinal vessel diameters in migraine patients during attack-free period. |
| Q37883455 | Chemical mediators of migraine: preclinical and clinical observations |
| Q34361372 | Chemokine targets in acute brain injury and disease. |
| Q50995076 | Choroidal thickness measurements in migraine patients during attack-free period. |
| Q35229878 | Clinical effects and mechanism of action of sumatriptan in migraine |
| Q60711535 | Current and emerging therapies for migraine prevention and treatment |
| Q48908221 | Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; a possible neurophysiological and neu |
| Q50465175 | Developmental changes of mast cell populations in the cerebral meninges of the rat. |
| Q51544635 | Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. |
| Q37357042 | Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists |
| Q37323725 | Distribution of 5-HT1F Receptors in Monkey Vestibular and Trigeminal Ganglion Cells |
| Q50210809 | Diverse effects of Brilliant Blue G administration in models of trigeminal activation in the rat. |
| Q91530180 | Does inflammation have a role in migraine? |
| Q50227033 | Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region |
| Q48148679 | Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis |
| Q73098697 | Effects of alniditan on neurogenic oedema in the rat dura mater and on contraction of rat basilar artery |
| Q36881119 | Effects of the 5-HT1 receptor agonists, sumatriptan and CP 93,129, on dural arterial flow in the rat. |
| Q36574510 | Emerging drugs for migraine prophylaxis and treatment. |
| Q36992954 | Emerging therapies for migraine |
| Q43411321 | Estrogen-Dependent Changes in Dura Mater Microvasculature Add New Insights to the Pathogenesis of Headache |
| Q43456765 | Evaluation of c-Fos immunoreactivity in the rat brainstem nuclei relevant in migraine pathogenesis after electrical stimulation of the trigeminal ganglion. |
| Q36233055 | Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. |
| Q84979025 | Experimental models of migraine |
| Q49122803 | Functional profile of almotriptan in animal models predictive of antimigraine activity |
| Q35872010 | Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater |
| Q28249721 | Future drugs for migraine |
| Q35873339 | GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges |
| Q42845105 | Gabapentin inhibits central sensitization during migraine |
| Q41554758 | Ganglionic axons in motor roots and pia mater |
| Q36353546 | Hypoxia facilitates neurogenic dural plasma protein extravasation in mice: a novel animal model for migraine pathophysiology |
| Q48171493 | Immunomodulatory Effect of Toll-Like Receptor-3 Ligand Poly I:C on Cortical Spreading Depression |
| Q34793049 | Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene‐related peptide |
| Q34500833 | Infection-mediated vasoactive peptides modulate cochlear uptake of fluorescent gentamicin |
| Q48230749 | Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivity |
| Q60737046 | Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility |
| Q71979029 | Intravascular substance P dilates cerebral parenchymal vessels through a specific tachykinin NK1 receptor in cats |
| Q27304508 | Intravital imaging of a massive lymphocyte response in the cortical dura of mice after peripheral infection by trypanosomes |
| Q43873034 | Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model |
| Q42433595 | KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion |
| Q57481750 | Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice |
| Q36255394 | Management of migraine in children and adolescents in the emergency department and inpatient setting |
| Q78019807 | Messenger molecules and receptor mRNA in the human trigeminal ganglion |
| Q37710416 | Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review |
| Q92499691 | Migraine and the trigeminovascular system-40 years and counting |
| Q84979035 | Migraine general aspects |
| Q35639004 | Migraine-like headache in a patient with complement 1 inhibitor deficient hereditary angioedema |
| Q36229186 | Migraine: current concepts and emerging therapies |
| Q34407137 | Modelling headache and migraine and its pharmacological manipulation |
| Q36995199 | Molecular mechanisms of migraine? |
| Q42847541 | Multiple mechanisms in the motor responses of the guinea-pig isolated urinary bladder to bradykinin |
| Q48508216 | Nerve growth factor and septal grafts: a study of behavioral recovery following partial damage to the septum in rats |
| Q37748431 | Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions |
| Q53835617 | Neurogenic inflammation and its role in migraine. |
| Q44478817 | Neurogenically Mediated Plasma Extravasation in Dura Mater: Effect of Ergot Alkaloids: A Possible Mechanism of Action in Vascular Headache |
| Q92826160 | Neuroimaging clues of migraine aura |
| Q42716757 | Neurokinin‐induced changes in pial artery diameter in the anaesthetized guinea‐pig |
| Q34272170 | Neuronal messengers in the human cerebral circulation. |
| Q42581141 | Neuropeptide Y Y2 receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms |
| Q45172171 | Neuropeptide Y- and substance P-like immunoreactive nerve fibers in the rat dura mater encephali |
| Q41330922 | Neuropeptides in dural fine sensory nerve endings--involvement in neurogenic inflammation? |
| Q28392631 | Neurovascular contributions to migraine: Moving beyond vasodilation |
| Q40850323 | New concepts of vascular headache. |
| Q52656846 | PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. |
| Q39127073 | Pathophysiology of Migraine: A Disorder of Sensory Processing |
| Q35872756 | Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation |
| Q47676203 | Perivascular neurotransmitters: Regulation of cerebral blood flow and role in primary headaches. |
| Q33709238 | Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy |
| Q28354243 | Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals |
| Q90194886 | Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service |
| Q35884327 | Post-triptan era for the treatment of acute migraine |
| Q37627012 | Reactive oxygen species induce procalcitonin expression in trigeminal ganglia glia |
| Q35026033 | Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). |
| Q43187841 | Release of immunoreactive substance P in the brain stem upon stimulation of the cranial dura mater with low pH - inhibition by the serotonin (5-HT1) receptor agonist CP 93,129. |
| Q48825363 | Release of immunoreactive substance P in the trigeminal brain stem nuclear complex evoked by chemical stimulation of the nasal mucosa and the dura mater encephali--a study with antibody microprobes |
| Q46794291 | Release of sensory neuropeptides from dural venous sinuses of guinea pig |
| Q60678467 | Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro |
| Q36836794 | Review of frovatriptan in the treatment of migraine |
| Q38254739 | Role of cortical spreading depression in the pathophysiology of migraine |
| Q30465785 | Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology |
| Q48289121 | Serotonin in migraine: theories, animal models and emerging therapies. |
| Q38208825 | Sphenopalatine ganglion stimulation for the treatment of cluster headache |
| Q90092577 | Step-Headache: A Distinct Symptom of Migraine |
| Q44516016 | Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice |
| Q47734282 | Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation |
| Q39485720 | Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache |
| Q34555756 | Targeting TRP channels for novel migraine therapeutics |
| Q46838016 | The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater |
| Q41574379 | The Role of Neurogenic Inflammation in Blood-Brain Barrier Disruption and Development of Cerebral Oedema Following Acute Central Nervous System (CNS) Injury |
| Q33843032 | The Role of Substance P in Secondary Pathophysiology after Traumatic Brain Injury |
| Q73205405 | The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system |
| Q35887963 | The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater |
| Q41576061 | The blood-brain barrier and the inflammatory response. |
| Q43685853 | The effect of adrenergic compounds on neurogenic dural vasodilatation |
| Q41578664 | The effects of tachykinins on inflammatory and immune cells |
| Q62441864 | The endolymphatic duct and sac of the rat: a histological, ultrastructural, and immunocytochemical investigation |
| Q41833775 | The inhibition of nicotine-evoked relaxation of the guinea-pig isolated basilar artery by some analgesic drugs and progesterone |
| Q34663175 | The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs |
| Q27008834 | The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine |
| Q42706973 | The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist |
| Q33952000 | The pharmacology of headache |
| Q38222871 | The role of substance p in ischaemic brain injury |
| Q48559123 | The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine |
| Q41757345 | The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles |
| Q42715132 | Time-dependent blockade of neurogenic plasma extravasation in dura mater by 5-HT1B/D agonists and endopeptidase 24.11. |
| Q34555809 | Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain |
| Q71993039 | Topography and distribution of nerve fibers in the posterior longitudinal ligament of the rat: an immunocytochemical and electron-microscopical study |
| Q42116885 | Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation |
| Q33838942 | Trigeminovascular fibers increase blood flow in cortical gray matter by axon reflex-like mechanisms during acute severe hypertension or seizures |
| Q67465992 | UK-14,304, R(−)-α-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms |
| Q49528803 | Understanding Spreading Depression from Headache to Sudden Unexpected Death. |
| Q43263208 | Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation |
| Q36261133 | Verisimilitude (or "truthlikeness") as an alternative to pro and cons: migraine and cluster headache mechanisms |
| Q38265392 | What is the evidence for the use of corticosteroids in migraine? |
| Q73509977 | [PET and Doppler sonography in headaches] |